Investment Analysts’ Recent Ratings Updates for Axsome Therapeutics (AXSM)

Axsome Therapeutics (NASDAQ: AXSM) recently received a number of ratings updates from brokerages and research firms:

• 3/6/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
• 3/3/2025 – Axsome Therapeutics had its price target raised by analysts at Robert W. Baird from $132.00 to $160.00. They now have an “outperform” rating on the stock.
• 3/3/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $153.00 price target on the stock.
• 2/27/2025 – Axsome Therapeutics had its price target raised by analysts at Morgan Stanley from $125.00 to $190.00. They now have an “overweight” rating on the stock.
• 2/26/2025 – Axsome Therapeutics had its price target raised by analysts at Mizuho from $195.00 to $212.00. They now have an “outperform” rating on the stock.
• 2/20/2025 – Axsome Therapeutics had its price target raised by analysts at HC Wainwright from $190.00 to $200.00. They now have a “buy” rating on the stock.
• 2/19/2025 – Axsome Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $153.00 price target on the stock.
• 2/19/2025 – Axsome Therapeutics had its price target raised by analysts at Royal Bank of Canada from $143.00 to $192.00. They now have an “outperform” rating on the stock.
• 2/19/2025 – Axsome Therapeutics had its price target raised by analysts at Truist Financial Co. from $190.00 to $200.00. They now have a “buy” rating on the stock.
• 2/19/2025 – Axsome Therapeutics had its price target raised by analysts at Needham & Company LLC from $133.00 to $153.00. They now have a “buy” rating on the stock.
• 2/18/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 2/12/2025 – Axsome Therapeutics had its price target raised by analysts at Wells Fargo & Company from $140.00 to $160.00. They now have an “overweight” rating on the stock.
• 2/11/2025 – Axsome Therapeutics had its price target raised by analysts at Mizuho from $137.00 to $195.00. They now have an “outperform” rating on the stock.
• 2/11/2025 – Axsome Therapeutics had its price target raised by analysts at Bank of America Co. from $143.00 to $167.00. They now have a “buy” rating on the stock.
• 2/11/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
• 2/11/2025 – Axsome Therapeutics is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $176.00 price target on the stock.
• 2/10/2025 – Axsome Therapeutics had its price target raised by analysts at Leerink Partners from $110.00 to $150.00. They now have an “outperform” rating on the stock.
• 2/10/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 2/3/2025 – Axsome Therapeutics was given a new $132.00 price target on by analysts at Robert W. Baird.
• 2/3/2025 – Axsome Therapeutics had its price target raised by analysts at Mizuho from $122.00 to $137.00. They now have an “outperform” rating on the stock.
• 2/3/2025 – Axsome Therapeutics had its price target raised by analysts at Truist Financial Co. from $180.00 to $190.00. They now have a “buy” rating on the stock.
• 1/31/2025 – Axsome Therapeutics had its price target raised by analysts at HC Wainwright from $180.00 to $190.00. They now have a “buy” rating on the stock.
• 1/29/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $139.00 price target on the stock.
• 1/24/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 1/21/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
• 1/13/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 1/13/2025 – Axsome Therapeutics had its price target raised by analysts at Truist Financial Co. from $150.00 to $180.00. They now have a “buy” rating on the stock.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $122.17 on Monday. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $139.13. The company has a market capitalization of $5.96 billion, a P/E ratio of -20.40 and a beta of 1.00. The firm has a 50 day moving average of $108.78 and a 200 day moving average of $97.83. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. As a group, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 22.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pitcairn Co. grew its position in Axsome Therapeutics by 3.4% in the 4th quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock worth $386,000 after purchasing an additional 148 shares during the period. Meridian Wealth Management LLC boosted its stake in shares of Axsome Therapeutics by 0.7% in the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock worth $1,791,000 after buying an additional 150 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Axsome Therapeutics by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company’s stock worth $326,000 after acquiring an additional 162 shares during the period. Arizona State Retirement System increased its position in Axsome Therapeutics by 1.8% during the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock valued at $766,000 after acquiring an additional 164 shares during the last quarter. Finally, Intrust Bank NA increased its position in Axsome Therapeutics by 6.9% during the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock valued at $239,000 after acquiring an additional 183 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.